A 38-year-old woman from Mumbai with a history of acute rheumatic fever at age 12 presents with palpitations and dyspnea on exertion. On examination, she has an opening snap followed by a mid-diastolic murmur at the apex. Echocardiography shows mitral stenosis with a valve area of 1.2 cm² and mean gradient of 18 mmHg. Left atrial diameter is 5.2 cm. She is in normal sinus rhythm. She has no prior history of atrial fibrillation or thromboembolism. What is the most appropriate next step in management?

Explanation

## Clinical Assessment This patient has **symptomatic moderate-to-severe mitral stenosis (valve area 1.2 cm², mean gradient 18 mmHg)** with **normal sinus rhythm** and **no prior thromboembolism or documented left atrial thrombus**. ### Key Point: **Percutaneous mitral balloon valvotomy (PMBV) is the procedure of choice for symptomatic mitral stenosis with favorable valve anatomy and no contraindications.** Anticoagulation strategy depends on individual thromboembolism risk factors, not solely on the decision to intervene. ### High-Yield: Mitral Stenosis Management Algorithm: ```mermaid flowchart TD A[Mitral Stenosis diagnosed]:::outcome --> B{Symptomatic?}:::decision B -->|No| C[Observe, regular echo]:::action B -->|Yes| D{Valve area & anatomy?}:::decision D -->|>1.5 cm² or unfavorable anatomy| E[Medical management]:::action D -->|≤1.5 cm² + favorable anatomy| F[PMBV candidate]:::action F --> G{Anticoagulation indication?}:::decision G -->|AF, prior TE, or LA thrombus| H[Warfarin + PMBV]:::action G -->|NSR, no TE history, no LA thrombus| I[Aspirin + PMBV]:::action E --> J[Beta-blocker for rate control]:::action ``` ### Criteria for PMBV Suitability: | Feature | Favorable | Unfavorable | |---|---|---| | Valve area | <1.5 cm² | >1.5 cm² | | Leaflet calcification | Absent/minimal | Extensive | | Commissural fusion | Mild | Severe | | Subvalvular disease | Minimal | Severe | | Left atrial thrombus | Absent | Present | | Mitral regurgitation | Mild | Moderate–severe | This patient has: - Valve area 1.2 cm² → symptomatic, meets threshold for intervention - No mention of heavy calcification or severe subvalvular disease → favorable anatomy - Normal sinus rhythm (no AF) - No prior thromboembolism and no documented LA thrombus ### Why Option B (Aspirin + PMBV) is Correct: Per ACC/AHA Valvular Heart Disease Guidelines and Harrison's Principles of Internal Medicine (21e, Ch. 282), **warfarin anticoagulation in mitral stenosis is indicated when there is: (1) atrial fibrillation (paroxysmal, persistent, or permanent), (2) prior systemic thromboembolism, or (3) documented left atrial thrombus.** This patient has none of these. In patients with normal sinus rhythm and no thromboembolism history, **aspirin is appropriate for primary prevention** and does not contraindicate PMBV. Warfarin is not indicated here because its bleeding risk outweighs benefit in the absence of established risk factors. ### Why Not Option A (Warfarin + PMBV)? Warfarin is **not indicated** in this patient because: 1. She is in **normal sinus rhythm** — no AF (paroxysmal, persistent, or permanent) 2. **No prior thromboembolism** documented 3. **No left atrial thrombus** on echocardiography While the left atrial diameter of 5.2 cm indicates LA enlargement (a risk factor for future AF), this alone does **not** constitute a current indication for warfarin per established guidelines. Anticoagulation is initiated when AF or thromboembolism is actually documented, not prophylactically for LA enlargement alone. ### Why Not Option C (Beta-blocker + Observe)? Beta-blockers are useful for rate control in AF or for symptom relief, but this patient is **symptomatic with a valve area of 1.2 cm²**, which meets the threshold for intervention (≤1.5 cm²). Observation alone would be inappropriate when a definitive, low-risk intervention (PMBV) is available and indicated. ### Why Not Option D (Mitral Valve Replacement)? MVR is reserved for patients who are **not candidates for PMBV** — i.e., those with unfavorable valve anatomy (heavy calcification, severe subvalvular disease), significant mitral regurgitation, or left atrial thrombus not amenable to anticoagulation. PMBV is always the **first-line intervention** when anatomy is favorable, as it avoids the risks of open-heart surgery and prosthetic valve complications. ### Clinical Pearl: **LA diameter >5.0 cm** increases future AF risk and warrants close monitoring, but does **not** by itself mandate warfarin in a patient currently in sinus rhythm with no prior thromboembolism. Anticoagulation decisions must be based on current, documented indications — not anticipated future events. [cite: Harrison 21e Ch 282; ACC/AHA 2021 Valvular Heart Disease Guidelines (Nishimura et al.)]